secwatch.observer — SEC 8-K summary
======================================

Issuer:     Denali Therapeutics Inc. (DNLI)
CIK:        0001714899
Form:       8-K
Filed at:   2022-10-20T23:59:59+00:00
Accession:  0001628280-22-026765
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Denali Therapeutics prices $275M public offering of 10.4M shares at $26.50/share
--------------------------------------------------------------------------------

- Priced 10,377,359 shares of common stock at $26.50 per share for gross proceeds of ~$275M.
- Underwriters granted 30-day option to purchase up to an additional 1,556,603 shares.
- Gross proceeds would be ~$316.2M if option exercised in full.
- Offering expected to close on or about October 24, 2022, subject to closing conditions.
- Goldman Sachs, J.P. Morgan, and Jefferies are joint book-running managers.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1714899/000162828022026765/0001628280-22-026765-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1714899/000162828022026765/dnli-20221019.htm
  HTML page:      https://secwatch.observer/filing/0001628280-22-026765

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer